Life-Changing Medicines.
Redefining Possibilities.
patient story
Hiding in Plain Sight: Learning the Signs of Narcolepsy
People living with narcolepsy may experience symptoms for more than a decade before receiving a proper diagnosis. That’s what happened to Meaghan – when she went undiagnosed and it felt like narcolepsy started to take over her life and limit her daily functioning.
Meaghan’s Story
Our science
What is Hepatic Veno-Occlusive Disease (VOD)? Understanding Symptoms and Signs of Progression
VOD, also known as sinusoidal obstruction syndrome, begins in the liver and can quickly affect other vital organs, most notably the kidneys and lungs. It is a rare and potentially deadly complication of hematopoietic stem cell transplantation (HSCT) occurring in approximately 9-14% of HSCT patients.
Learn More
News and Events
January 6, 2020
Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
December 30, 2019
Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
December 19, 2019
PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.
Jazz strives to create a workplace culture that supports a diverse, multicultural workforce and provides an inclusive environment where all employees are empowered to contribute and succeed.
See all News
Jazz Pipeline
PRE-CLINICAL
Oxybate
Once Nightly Formulation

CombiPlex
Solid tumors candidate

CombiPlex
Hem/Onc exploratory activities

JZP-341 (Long-acting Erwinia asparaginase)2
ALL/other hematological malignancies

Recombinant Pegaspargase1
Hematological malignancies

Defibrotide
Exploratory activities

Exosome NRAS candidate2
Hematological malignancies

Exosome STAT3 candidate2
Hematological malignancies

Exosome-based candidates2
Solid tumors/ Hematological malignancies

Pan-RAF Inhibitor Program
RAF & RAS mutant tumors

PHASE 1
CPX-351 + gemtuzumab3
R/R AML or HMA Failure
MDS

CPX-351 + venetoclax
Low Intensity Therapy for first-line, unfit AML (Phase 1b)

CPX-351 + various targeted agents
First-line, fit AML (Phase 1b)

CPX-3513
Low Intensity Dosing for higher risk MDS

IMGN6321
CD123+ Hematological malignancies

IMGN632 +/- venetoclax/azacitidine1
CD123+ AML (Phase 1b/2)

PHASE 2
JZP-3854
Essential tremor (Phase 2b)

Defibrotide
Prevention of aGvHD

Defibrotide
Prevention of CAR-T associated neurotoxicity

CPX-351 + venetoclax3
de novo or R/R AML

CPX-3515
HR-MDS (EMSCO)

CPX-3515
R/R AML (COG)

CPX-3514,5
Newly diagnosed older adults with HR-AML

CPX-351 + venetoclax4,5
HR-AML

PHASE 3
JZP-258
Idiopathic hypersomnia

Solriamfetol
EDS in MDD4

Defibrotide
Prevention of VOD

CPX-3515
AML or HR-MDS (AML19 & AML18)

CPX-3515
Newly diagnosed adults with standard- and HR-AML (AMLSG)

CPX-3514,5
Newly diagnosed pediatric patients (COG)

Lurbinectedin6
Relapsed SCLC (ATLANTIS)

JZP-458 (recombinant Erwinia asparaginase)
ALL/LBL (pivotal Phase 2/3)

REGULATORY
Solriamfetol EU
EDS in OSA and Narcolepsy

JZP-258
Cataplexy & EDS in narcolepsy4

Lurbinectedin6
Relapsed SCLC

Neuroscience
Hematology/Oncology
1Opt-in opportunity
2Partnered collaboration
3Jazz & MD Anderson Cancer Center collaboration study
4Planned
5Cooperative group study
6Subject to the closing of the license transaction with PharmaMar for lurbinectedin upon HSR clearance

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
More About Jazz
Living Our Values

Careers at Jazz

Clinical Trials

Learn More

By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.
Our Medicines